# UCD19 CarT in Treatment of Pediatric B-ALL and B-NHL

> **NCT04544592** · PHASE1,PHASE2 · RECRUITING · sponsor: **University of Colorado, Denver** · enrollment: 45 (estimated)

## Conditions studied

- B-cell Acute Lymphoblastic Leukemia
- B-cell Non Hodgkin Lymphoma

## Interventions

- **DRUG:** CD19CAR-CD3Zeta-4-1BB-Expressing Autologous T-Lymphocyte Cells

## Key facts

- **NCT ID:** NCT04544592
- **Lead sponsor:** University of Colorado, Denver
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-03-10
- **Primary completion:** 2026-06
- **Final completion:** 2026-07
- **Target enrollment:** 45 (ESTIMATED)
- **Last updated:** 2026-04-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04544592

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04544592, "UCD19 CarT in Treatment of Pediatric B-ALL and B-NHL". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT04544592. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*